Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (DE:12X1)
BERLIN:12X1
Anavex Life Sciences (12X1) Stock Price & Analysis
0 Followers
12X1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€3.05 - €9.32
Previous Close€3.3
Volume0.00
Average Volume (3M)1.69K
Market Cap
€282.77M
Enterprise Value€148.60M
Total Cash (Recent Filing)$143.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta0.99
Next Earnings
May 09, 2024EPS Estimate
-€0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding82,112,511
10 Day Avg. Volume0
30 Day Avg. Volume1,692
Standard Deviation0.27
R-Squared0.01
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)2.23
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.95
Forecast
1Y Price Target
€30.27Price Target Upside811.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Anavex Life Sciences News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressPipeline advances with developments in various programs, including the initiation of a Marketing Authorization Application for blarcamesine in Alzheimer's disease.
Financial HealthAnavex ended the fiscal quarter with strong financials, having significant cash reserves, indicating resources to fund operations for the foreseeable future.
Regulatory MilestonesAnavex has received positive feedback from regulators regarding the submission of an application for approval of blarcamesine in Europe to treat Alzheimer's disease.
Bears Say
Clinical TrialsRisk of clinical trial failure for blarcamesine could significantly impact the stock as successful trials are crucial for drug approval and market entry.
Drug Approval And LaunchFailure to obtain approval for blarcamesine across its target indications poses a substantial threat to the stock, hindering its prospects for commercial success.
Financial RiskPotential long-term dilution risk may affect shareholder value if the company seeks additional capital to fund its operations before blarcamesine becomes profitable.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.33% Other Institutional Investors
99.67% Public Companies and
Individual Investors
12X1 FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest stock price was €3.04 and its highest was €9.32 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Currently, no data Available
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is May 09, 2024 which is in 5 days.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on Feb 07, 2024. The company reported -€0.103 earnings per share for the quarter, beating the consensus estimate of -€0.135 by €0.033.
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate is -€0.1.
How many shares outstanding does Anavex Life Sciences have?
Currently, no data Available
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of -€0.103 in its last earnings report, beating expectations of -€0.135. Following the earnings report the stock price went up 7.809%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Among the largest hedge funds holding Anavex Life Sciences’s share is Sheaff Brock Investment Advisors LLC. It holds Anavex Life Sciences’s shares valued at 347K.
---
Anavex Life Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€30.27 (811.16% Upside)
€30.27 (811.16% Upside)
Blogger Sentiment
Bullish
DE:12X1 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $375.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.00%
12-Months-Change
Fundamentals
Return on Equity
-31.89%
Trailing 12-Months
Asset Growth
-0.20%
Trailing 12-Months
Company Description
Anavex Life Sciences
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
---
12X1 Earnings Call
Q1 2024
0:00 / 0:00
---
12X1 Stock 12 Months Forecast
Average Price Target
€30.27
▲(811.16% Upside)
Technical Analysis
Anavex Life Sciences
―
Avrobio
―
Avinger
―
Axsome Therapeutics
―
Sarepta Therapeutics
―
Best Analysts Covering 12X1
1 Year
1 Year Success Rate
1/21 ratings generated profit
1 Year Average Return
-38.05%
reiterated a buy rating 3 months ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 4.76% of your transactions generating a profit, with an average return of -38.05% per trade.
---